

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first...
You can purchase shares of Greenwich LifeSciences (NASDAQ:GLSI) through any online brokerage.
Other companies in Greenwich LifeSciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Greenwich LifeSciences has a consensus price target of $70.00.
The stock price for Greenwich LifeSciences (NASDAQ: GLSI) is $20 last updated November 20, 2026 at 5:49 PM EST.
There are no upcoming dividends for Greenwich LifeSciences.
Greenwich LifeSciences does not have any upcoming earnings scheduled.
There is no upcoming split for Greenwich LifeSciences.
Greenwich LifeSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane...